多西他赛联合希罗达治疗晚期乳腺癌的临床分析  被引量:5

Clinical observation of docetaxel and xeloda in treatment of advanced breast cancer

在线阅读下载全文

作  者:韦玮[1,2] 张良明[1] 

机构地区:[1]青岛大学医学院附属烟台毓璜顶医院肿瘤内一科,山东烟台264000 [2]青岛大学医学院

出  处:《中国医药科学》2013年第5期80-81,共2页China Medicine And Pharmacy

摘  要:目的评价多西他赛联合希罗达治疗晚期乳腺癌的临床疗效和不良反应。方法 30例晚期乳腺癌患者均给予多西他赛75mg/m2,静滴第1天;希罗达1250mg/m2,餐后口服,2次/d,连续服用14d,治疗周期为21d,2个周期后评价疗效和不良反应。结果本组30例患者中完全缓解(CR)3例,部分缓解(PR)14例,稳定(SD)7例,疾病进展(PD)6例,总有效率为56.7%,肿瘤控制率为80.0%。主要不良反应为骨髓抑制、胃肠道反应、手足综合征、皮肤色素沉着等,对症处理均可耐受。结论多西他赛联合希罗达作为二线方案治疗晚期乳腺癌的疗效较好,而且不良反应轻,可以作为蒽环类药物治疗失败的晚期乳腺癌的解救方案。Objective To observe the clinical efficacy and adverse effect of docetaxel and xeloda in treating advanced breast cancer. Methods The patients with advanced breast cancer were treated with docetaxel and xeloda. Each patient received 2 cycles chemotherapy at least. The efficacy and side effect were reviewed after chemotherapy. Results Among these 30 patients, there were 3 complete remissions, 14 partial remissions, 7stable diseases, and 3 progression diseases. The clinical benefit response (CR+ PR) was 56.7%.The tumor control rate (CR+ PR+ SD) was 80.0%. The main side effects were myelosuppression, hand-foot syndrome, nausea and vomiting, diarrhea and were tolerable. Conclusion Docetaxel combined with xeloda is effective and well tolerable in treating advanced breast cancer as secondline chemotherapy. This regimen can be used in the patients after failure from treatment by anthracycline.

关 键 词:多西他赛 希罗达 乳腺癌 化学疗法 

分 类 号:R737.9[医药卫生—肿瘤]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象